Worldwide, an estimated two billion people are unable to reap the full benefits of modern medicine. For reasons that range from high costs to inadequate distribution, they lack access to medications for preventable or treatable diseases such as HIV/AIDS, malaria, pneumonia, and tuberculosis. Global pharmaceutical companies, meanwhile, have both the ability to provide critical medications and an incentive to extend their reach into the regions where those two billion people live. After all,…

To read this article and start a full year of unlimited online access, subscribe now!

Already a subscriber?

Need to register for your premium online access,
which is included with your paid subscription?

Support SSIR’s coverage of cross-sector solutions to global challenges. 
Help us further the reach of innovative ideas. Donate today.

Read more stories by Jayasree K. Iyer.